Friday, July 10, 2026

pharma · Obesity, Overweight · Type 2 Diabetes

Eli Lilly and

Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 1

Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
1876 Founded
55,860 Employees
EMA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Founded
1876
Employees
55,860
Programs
107
Drugs
99
Patents
0
Clinical program

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 · other · Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors for Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Internal code J5M-OX-JOXA

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Eli Lilly Co.
Phase
Phase 1
Modality
other
Indication
Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor
Status
active
Trials
1

Clinical trials